Many human malignancies lack de novo biosynthesis of arginine (Arg) as the key enzyme argininosuccinate synthetase 1 (ASS1) is silenced. These tumors acquire ectopic Arg for survival, and depleting this source by Arg-depleting recombinant enzyme ADI-PEG20 results in cell death. Mechanisms underlying Arg auxotrophy in these tumors and how they respond to Arg-auxotrophic stress are poorly understood. Here, we report that an immediate-early event of Arg-auxotrophic response involves reactive oxygen speciesmediated secretion of Gas6, which interacts with its receptor Axl and activates the downstream Ras/PI3K/Akt growth signal leading to accumulation of c-Myc by protein stabilization. Arg-auxotrophic challenge also transcriptionally upregulates c-Myc expression, which provides a feedback mechanism to enhance Axl expression. c-Myc is a positive regulator of ASS1, but elevated ASS1 provides a feedback mechanism to suppress c-Myc and Axl. Our results revealed multiple inter-regulatory pathways in Arg-auxotrophic response, consisting of Axl, c-Myc and ASS1, which regulate Arg homeostasis and ADI-PEG20 sensitivity. These pathways provide potential targets for improving the efficacy of treating Arg-auxotrophic tumors using Arg-deprivation strategies.
INTRODUCTION
L-arginine (Arg) is a semiessential amino acid. Malignant cells require sufficient amounts of Arg for protein biosynthesis to sustain their highly proliferative activity. Arg can be de novo synthesized from citrulline and aspartate by argininosuccinate synthetase 1 (ASS1). ASS1 deficiency causes citrullinemia, a rare autosomal recessive disease. 1 Alternatively, Arg can be obtained from the extracellular milieu through cationic amino-acid transporters. It has been reported that sub-populations of various human malignancies in many different lineages do not produce sustainable amounts of Arg and require extracellular Arg for survival because these tumors express very low levels of ASS1. 2, 3 The Arg-degrading recombinant enzymes, pegylated arginine deiminase (ADI-PEG20, hereafter ADI), which digests Arg into citrulline and ammonia, and human arginase 1, which digests Arg into ornithine and urea, induce Arg-auxotrophic stress leading to cell death (see reviews in Feun and Savaraj 2 and Kuo et al. 3 ). These recombinant proteins have been in various stages of clinical development for targeting Arg-auxotrophic tumors. 4 An important mechanism of Arg-auxotrophic response is induction of ASS1 expression, resulting in resistance to Arg-deprivation treatment.
We previously demonstrated that induction of ASS1 expression by Arg deprivation involves derepression of hypoxia-inducible factor 1α (HIF-1α) by downregulation but by upregulation of c-Myc, which replaces HIF-1α to upregulate ASS1 expression. 5 We further demonstrated that upregulation of c-Myc follows the signal-transduction mechanism involving Ras → PI3K/Akt/ERK → GSK3β, where ERK phosphorylates c-Myc, resulting in c-Myc accumulation by suppressing proteasomal degradation. 6 However, how Arg-auxotrophic stress is sensed in activating the Ras signal is not known. We report here that reactive oxygen species (ROS)-related immediate-early activation of Gas6/Axl followed by a c-Mycmediated transcriptional upregulation of Axl is involved in Argauxotrophic response, leading to enhanced expression of ASS1. Elevated ASS1 expression provides a feedback mechanism, and suppresses c-Myc and Axl expression, constituting a selfregulatory mechanism of Arg-auxotrophic management, which has implications for targeted therapy of Arg-auxotrophic tumors.
RESULTS

Activation of Axl in response to ADI in melanoma cells
To investigate whether activation of receptor tyrosine kinases (RTKs) is involved in Arg-auxotrophic response that activates Ras signaling, 6 we used lysates of A2058 cells treated with or without ADI for 15 min to probe an array of 42 antiphosphotyrosine receptor antibodies in duplicate and observed that Axl was the predominant RTK activated (Figure 1a ). We confirmed this using western blotting, which demonstrated a dose-dependent activation of Axl by ADI (Figure 1b ). Activated Axl in A2058 cells can be seen as early as 5 min after ADI treatment, but disappears after 30 min of exposure ( Figure 1c ). This transient induction of Axl was also seen in A2058 cells grown in Arg-free medium (Figure 1d ). Activation of Axl by ADI was also seen in another melanoma cell line SK-Mel-2 (not shown) and in breast cancer cell line MDA-MB-231, but the kinetics of induction was delayed and persistent through an 1-h treatment (Figure 1e ). No activation of Axl and Akt was seen in A375 cells (Figure 1f ), consistent with our previous observations for the non-inducibility of this cell line by ADI treatment. 6 These observations revealed substantial heterogeneity in response to Arg deprivation in human cancer cell lines. Moreover, while no p-Axl was detectable in A2058 cells treated with ADI or grown in Arg(− ) conditions after 30 min treatment, p-Akt levels continued to increase thereafter, suggesting that activation of Akt is a downstream event.
To demonstrate the role of Axl in Arg-auxotrophic response, we introduced the dominant-negative Myc-tag Axl mutant (Axl-DNMyc, K558R in the kinase domain). Overexpression of Axl-DN-Myc abolished the ADI-induced Ras/Akt signal ( Figure 1g ). Axl is a membrane-bound RTK with extracellularly located ligand-binding domain. A truncated form of human Axl known as soluble Axl (sAxl) containing extracellular ligand-binding domains was found in the plasma of leukemia patients. 7 sAxl acts as a 'sponge' to neutralize Gas6 by preventing it from binding to the native Axl receptor. Expression of sAxl suppresses Axl signaling induced by ADI (Figure 1h ). These results demonstrated that Axl has an important role in Arg-auxotrophic response.
Gas6 secretion leads to Axl activation in response to ADI treatment The ligand of Axl is Gas6. 7 Because melanoma cells, including those described in this study, express undetectable amount of Gas6 by western blotting, we used MDA-MB-231 cells, which express high amount of Gas6 and is also auxotrophic for Arg. 6 Axl activation can be ligand-dependent or -independent. Because the ligand-binding domain of Axl is extracellularly located, liganddependent activation of Axl requires Gas6 externalization.
We treated MDA-MB-231 cells with ADI for different lengths of time. We found a time-dependent reduction of cellular Gas6 (endo-Gas6) with correspondingly increased ectopic Gas6 in culture media (ex-Gas6) (Figure 2a ). For Gas6 to interact with Axl, Gas6 has to be enriched in the plasma membrane. To demonstrate enhanced membrane association of Gas6 in ADI treatment, we fractionated cell lysates into cytoplasmic (C), membrane (M) and nuclear (N) fractions. Cross-contamination in these three fractions was minimal as evidenced by the distributions of α-tubulin for cytosol, Na + /K + ATPase for membrane and lamin B for nucleus as markers. We found that ADI treatment resulted in Gas6 enrichment in the membrane fraction, whereas p-Akt and c-Myc enrichment in the nuclear fraction (Figure 2b ). These results demonstrated that ADI triggers Gas6 release into the medium to activate Axl. The importance of Gas6 in Argauxotrophic response was further demonstrated using two Gas6 short hairpin RNAs (shRNAs) showing that knockdown of Gas6 abolished Axl activation (Figure 2c ) and enhanced the cell killing by ADI (Supplementary Figure S1) , whereas overexpression of Gas6 enhanced Axl activation (Figure 2d ).
Gas6 has two important structural features for its bioactivity. The C terminus contains 'sex-hormone-binding globulin' domain, which binds to the immunoglobulin domains of the receptor. The N terminus of Gas6 is rich in glutamic acids (Gla domain). 8 The γ-hydroxyl groups of these glutamic acid residues are posttranslationally carboxylated in a vitamin K-dependent modification. We used the Gas6 inhibitor warfarin, which inhibits γ-glutamylcarboxyltransferase and prevents γ-carboxylation of Gas6. 9 We found that warfarin suppressed ADI-induced Axl Figure S2) . Combination of warfarin and ADI exhibits additive cell-killing effects as determined by SRB ( Figure 2f ) and apoptosis (DNA fragmentation) assays (Figure 2g ).
Many small molecules have been developed to inhibit RTKs and some have been shown against Axl, although no inhibitor has been demonstrated to be clearly Axl-specific. 10 SKI-606 (bosutinib) is a Food and Drug Administration-and European Medicines Agency-approved agent for treating Philadelphia chromosome- Gas6 secretion induced by ADI follows conventional protein translocation mechanism that is regulated by ADI-induced ROS Under non-stressed conditions, γ-carboxylation of Gla domain allows Gas6 to bind to phosphatidylserine at the inner, cytoplasmfacing leaflet of the plasma membrane under the control of P4-ATPases or flippases and plasma membrane scramblases. 15, 16 In an apoptotic cell, phosphatidylserine is displayed on the extracellular membrane surface because of disabled flippases and enhanced phospholipid scramblases, 17 resulting in externalization of Gas6. 18, 19 We investigated whether Gas6 externalization follows unconventional membrane translocation mechanism or conventional protein translocation mechanism, which requires a N-terminal signal (leader) sequence that navigates secretory protein to the cell surface through the vesicular secretion pathway via endoplasmic reticulum and Golgi apparatus. Unconventional secretory proteins lack signal peptides and their transport is not affected by inhibitors to endoplasmic reticulum/Golgi. 20 Using SignalP-20 program (http://www.cbs.dtu.dk/services/SignalP/), we found that Gas6 contains a 32-amino-acid signal peptide sequence located at the N terminus (Supplementary Figure S5) . We found that treating MDA-MB-231 cells with brefeldin A, which is a potent inhibitor of protein secretion by inducing Golgi dissembles, 21 and golgicide A, which is a highly specific inhibitor of Golgi brefeldin A resistance factor 1, 22 suppressed ADI-induced Gas6 externalization (Figure 3a) . These results suggested that ADIinduced Gas6 release follows a conventional secretory pathway.
Gas6 contains many cysteine residues (amino acids 119, 124, 141, 142, 158, 164, 168,177, 283 and 570, which could be involved in bisulfide linkages for Gas6 function). 23 These bisulfide bridges could be sensitive to oxidative regulation. We hypothesized that ADI treatment generates ROS to promote Gas6 secretion. Because induction of Gas6 release by ADI occurs within minutes, we preloaded MDA-MB-231 and A375 cells with the ROS probe dihydrorhodamine for 30 min. We found that a time-dependent increased ROS production following ADI treatment in MDA-MB-231 cells is an immediate-early event (Figure 3b , left). ADI treatment of A375 cells seems to reduce ROS levels, that is, a left shift of the fluorescence profiles (Figure 3b , right). These findings are consistent with the differential inducibility of Gas6/Axl by ADI between these two cell lines (Figures 1e and f) . Although the magnitudes of ROS induction using this assay system were minor, the results are reproducible (three experiments) and also are consistent with the recent published results using longer treatment time of ADI (see below). We next investigated whether ADI-mediated oxidative status affects Gas6 secretion. Treating MDA-MB-231 cells with antioxidant N-acetyl-L-cysteine (NAC) reduced ADI-induced Gas6 release, as well as endogenous Gas6 level, whereas treating with pro-oxidants N-ethylmaleimide (NEM) or H 2 O 2 promote Gas6 release and activation of the Axl signal (Figure 3c ). These results suggested that ADI-induced Gas6 secretion is mediated by an ROS-related mechanism. Although the precise mechanism how NAC alone reduces Gas6 expression is unknown, it may be because of the unstable nature of Gas6 under reducing conditions (disruption of the disulfide bridge), because Gas6 is a redox-sensitive protein.
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Shp2 is an integral part of the Gas6/Axl activation signal To elucidate how Gas6/Axl activation transmits into its downstream Ras/Akt signals, we performed immunoprecipitation (IP) of lysates from ADI-treated or -untreated cells with anti-Axl antibody followed by western blotting. Whereas Gas6 was co-precipitated with Axl in the untreated cells, ADI treatment enriched Gas6 association with Axl and Shp2 (Src homology-2 domain-containing protein tyrosine phosphatase 2), which has been demonstrated to transmit activated RTK signal to Ras/PI3K/Akt 25 ( Figure 4a ). To strengthen these findings, we carried out similar experiment in a time-course manner. We found that kinetics of Axl, Gas6 and Shp2 associations mirror the kinetics of p-Axl induction in MDA-MB-231 cells (Figures 1e and 4b) . Similarly, Shp2 immunoprecipitates probed by Axl or phosphorylated tyrosine antibodies in lysates prepared from a time-course treatment of A2058 cells with ADI also follows the kinetics of p-Axl activation in this cell line (Figures 1c and 4c) . Similar results were obtained using antiphosphorylated tyrosine in IP, followed by western blotting with antiShp2 and anti-Axl antibodies (Figure 4c) .
To demonstrate the role of Shp2 in ADI-induced Gas6/Axl signal, we used an Shp2-DN, which contains a catalytically inactive mutation (C459S). Expression of C459S-mutant abolished ADImediated Ras/Akt activation (Figure 4d) . Similar results were observed using an shRNA approach (Figure 4e) . Overexpression of wild-type Shp2 induces Akt activation regardless of ADI treatment (Figure 4f) . These results demonstrated involvement of Shp2 in the activation of Gas6/Axl/Ras/Akt signaling in response to ADI. c-Myc is involved in transcriptional regulation of Axl expression by ADI Activation of Gas6/Axl to Arg-auxotrophic challenge occurs within minutes. However, we found that longer challenge increased the expression of Axl and several downstream effectors as determined by western blotting ( Figure 5 ). Induction of Axl by ADI was also observed at the mRNA levels as measured by quantitative realtime PCR (Figure 5b ), suggesting that transcriptional regulation is involved.
In examining the proximal Axl promoter sequence, we found three putative E-box sequences located within −1495 nt from the transcriptional start site, designated E-box 1, E-box 2 and E-box 3 from the 5′ side. We constructed reporter recombinants containing their respective wild-type E-box sequences and mutations at each of these boxes (Figure 5c, underscored) . We transfected these recombinant DNA into A2058 cells and treated them with ADI or were grown in Arg-free medium. Figure 5d shows that these treatments enhanced expression of the wild-type reporter, but not in all the three mutants (mE1, and so on), demonstrating that these E-boxes are involved in transcriptional regulation of Axl by ADI. As c-Myc is a transcriptional regulator that interacts with E-box sequences, we hypothesized that c-Myc is involved in the transcriptional regulation of Axl by ADI. Chromatin IP (ChIP) demonstrated enhanced c-Myc binding to each of these E-boxes (Figure 5e ). Moreover, depleting c-Myc using shRNA approach suppressed Axl induction by ADI in the reporter assay (Figure 5f ) and in cultured cells (Figure 5g ). These results demonstrated that c-Myc transcriptionally upregulates Axl expression under Arg-auxotrophic stress conditions. The inter-regulatory network of c-Myc, Axl and ASS1 in Arg-auxotrophic response We previously demonstrated that ADI treatment enhanced c-Myc accumulation by inhibiting the proteasomal degradation mechanism. 6 Using quantitative real-time PCR, we observed that c-Myc mRNA was induced by ADI within 24 h after ADI treatment (Figure 6a ). We hypothesized that enhanced c-Myc mRNA levels by ADI is autoregulated through the E-box located − 2274 nt at the 5′ side of c-Myc. We constructed reporter plasmids containing wildtype E-box and the mutant form (Figure 6b ). Although the expression of the reporter in wild-type construct was induced in A2058 cells under Arg-deprivation conditions, mutation at this site reduced the expression levels (Figure 6c) . Similar results were also observed in MDA-MB-231 cells (Supplementary Figure S6) . Knockdown of c-Myc in the transfected cells also diminished the levels of reporter induction under these treatments (Figure 6d ). Furthermore, a ChIP assay demonstrated enhanced binding of c-Myc to the E-boxes located at the c-Myc promoter and ASS1 promoter (positive control) (Figure 6e ). These results demonstrated that ADI-induced c-Myc expression is transcriptionally autoregulated itself.
ADI-induced c-Myc expression moves forward to induce ASS1 expression. 5, 6 Using a transfection approach, we observed that overexpression of ASS1 can negatively regulate c-Myc and Axl expression in western blotting assay (Figure 6f) . Suppression of c-Myc and Axl expression by the elevated ASS1 is transcriptionally regulated as demonstrated by ChIP assay, which shows reduced bindings of c-Myc to the E-boxes located in their respective promoters (Figure 6g) , and by reporter assay using Myc-2791-Luc and Axl-1495-Luc reporters, respectively (Figure 6h ). Taken together, these results support feedback regulation of c-Myc and Axl by ASS1.
Reduced Gas6/Axl expression is associated with Arg auxotrophy in melanoma cells
The above results suggest that deficiency of Gas6/Axl signal is an important mechanism of Arg auxotrophicity. To substantiate this finding, we performed western blot analyses of Gas6, Axl and ASS1 in a panel of 15 melanoma cell lines (Figure 7a, lanes 1-15) . We found that all other cell lines express much reduced Axl, except SB2 line (lane 15), which expresses detectable Axl. Expression of Axl in A2058, A375 and SK-Mel-2 could only be seen on autoradiograms upon long-term exposure, whereas Gas6 and ASS1 expression was virtually undetectable in all melanoma cell lines even upon prolonged exposure using MDA-MB-231 breast and SKOV3 ovarian cancer cell lines as references (Figure 7a ). Ectopic expression of recombinant Gas6 in six randomly selected melanoma cell lines conferred Axl activation by ADI in all these cell lines (Figure 7b ), demonstrating that Gas6 controls Arg-auxotrophic response.
Correlations of Gas6, Axl and ASS1 expression in melanoma tissues
We immunostained an array of 96 tissue specimens in duplicates from 48 individuals, consisting of 4 normal skin, 4 benign hyperplasia, 2 basal cell carcinoma, 2 squamous cell carcinoma, 24 primary melanoma and 12 metastatic melanoma. We found that Gas6 expression was virtually not detectable, except in one case with basal cell carcinoma. Axl expression was also undetectable, except low levels of expression in one each of benign and basal cell carcinoma, and two cases in primary melanoma. ASS1 expression was undetectable in all the melanomas. Examples of Gas6, Axl and ASS1 immunohistochemistry are shown in Figure 7c , using either MDA-MB-231 or kidney tissue as positive controls and A2058 cells as negative controls for these stainings. We also ruled out the contribution of melanin in immunohistochemistry, because no staining was observed using hematoxylin and eosin staining. Collectively, these results demonstrated that Gas6, Axl and ASS1 expression levels were low in human melanoma tissues, consistent with the cell line data.
We next examined the expression levels of these genes in human melanoma tissues using the data from the TCGA database. We found that the expressions of Gas6, Axl and ASS1 in 103 skin cutaneous melanoma are significantly low, compared with that against the expression in ovarian cancers as a baseline (data not shown). Moreover, we found that expression levels between Gas6 and Axl mRNA (Figure 7d, left) and between Gas6 and ASS1 mRNA (Figure 7d, middle) show significantly positive correlation (P = 0.003, P o 0.0001, respectively), whereas the correlation between Axl and ASS1 mRNA had borderline significance (Figure 7d , right, P = 0.045). For comparisons, we found significantly positive correlation between Gas6 and Axl and between Gas6 and ASS1 mRNA (both P o 0.0001), whereas no correlation between Axl and ASS1 mRNA (P = 0.12), in ovarian cancers (not shown). These results have important implications of the Gas6/Axl/ASS1 axis in Arg auxotrophicity in malignant melanoma. The poor correlation between Axl and ASS1 expression may suggest that multiple mechanisms are involved in the regulation of these genes in other tumor types. Although little is known about Axl regulation, previous studies showed that multiple mechanisms are involved in ASS1 regulation, including DNA methylation, 26 Ca 2+ -dependent PKCα-mediated protein phosphorylation, 27 cAMP-mediated PKA signal 28 and transcription factor PPARγ. 29 Elevated expression of ASS1, c-Myc, Axl and Gas6 mRNA in primary cultures derived from ADI-PEG20-treated melanoma patients We established two pairs of primary cultures from tumor biopsies of melanoma patients before ADI-PEG20 treatment and after failure of the treatment from the previous clinical study. 30 We determined mRNA levels of ASS1, c-Myc, Axl and Gas6 by quantitative real-time PCR in these cells. We found significantly increased expression of all these mRNAs in cultured cells from ADI-resistant patients as compared correspondingly with those from patients before the treatment. In both patients, ASS1 and c-Myc mRNA levels were increased two-to eightfold, whereas Axl and Gas6 mRNA were increased 30-60% (Po 0.05; Figure 7e ). These results showed that within the limited available samples, elevated expression of ASS1, c-Myc, Axl and Gas6 expression seems to associate with treatment failure of ADI in melanoma patients. Further studies with large sample size are needed to validate this finding.
DISCUSSION
Arg auxotrophy provides a metabolic vulnerability for targeted therapy using Arg-deprivation strategies in cancer chemotherapy. In this communication, we elucidated the molecular pathways underlying how cancer cell respond to Arg-auxotrophic challenge, and the results are schematically depicted in Figure 8 . We demonstrated that ROS mobilization, which stimulates the Gas6/Axl signal, is a very early event in Arg-auxotrophic response. Gas6 is a vitamin K-dependent ligand for TAM receptor family, which consists of Tyro3, Axl and Mer, 31 and Axl has the highest affinity for Gas6 among all. 32 By interacting with its receptors, Gas6 has important roles in multiple physiological and pathophysiological functions, including innate immunity, vasculature, atherosclerosis and thrombosis. 19, 33 Gas6 and Axl have been found overexpressed in many human malignancies (reviewed in Laurance et al., 33 Paccez et al. 34 and Verma et al. 35 ), and that overexpression of Axl is correlated with poor prognosis for some cancers. 36, 37 Moreover, upregulation of Axl has been demonstrated to develop acquired resistance to many chemotherapeutics, 34, 38 including inhibitors of epidermal growth factor receptor, [39] [40] [41] BRAF v600 (PLX4720) 42 and MEK (PD0325901 and AZD6244). 43 The present results demonstrated that Axl is involved in the regulation of ASS1, resulting in acquired resistance to Arg-deprivation chemotherapeutics, expanding the role of Axl in cancer chemotherapy.
Activation of Gas6/Axl in Arg-auxotrophic response is stimulated by ROS. This occurs within minutes. Additional support for the involvement of ROS in Gas6/Axl signaling is provided by the use of antioxidant NAC, which suppresses the activation and pro-oxidants, which promotes the activation. It has recently been reported that prolong treatment (24 h) of MDA-MB-231 cells with ADI induces ROS and mitochondrial fragmentation, leading to autophagy. 44 Our results suggested that generation of ROS is an early event that drives Arg-auxotrophic response of Gas6/Axl activation. However, how Arg starvation elicits ROS production requires further investigation.
Our results also demonstrated that activation of Axl signal by Arg starvation follows biphasic kinetics, that is, immediate-early activation by protein phosphorylation and subsequent transcriptional upregulation. Transcriptional upregulation of Axl is mediated by c-Myc, which is also regulated by Arg deprivation in a biphasic mode. Upregulated c-Myc then provides a feedback mechanism to enhance Axl transcription, thereby amplifying the downstream Ras signal. Meanwhile, c-Myc also provides a feedforward mechanism to upregulate ASS1 expression (Figure 8 ). Upregulated ASS1 not only promotes Arg biosynthesis to relieve Arg-auxotrophic pressure but also provides a feedback mechanism to downregulate c-Myc and Axl expression. This feedback mechanism provides a self-guarding mechanism for ASS1 homeostasis control because elevated expression of ASS1 may result in the overproduction of argininosuccinate, which is cytotoxic. 45 Furthermore, the self-regulatory mechanism of ASS1 may be an integral part of metabolic flux in urea cycle regulation. Recent study demonstrated that several enzymes in the urea cycle metabolism are coregulated, including ASS1, argininosuccinate lyase, nitric oxide synthase and cationic amino-acid transporter 1 by forming a supermolecular complex that regulates metabolic flux. 46 Collectively, our present results and those described previously 6, 14 establish an intricate network consisting of inter-regulatory and selfregulatory loops that control Arg homeostasis (Figure 8) .
The multiple inter-regulatory loops place c-Myc in the center of the network, in which c-Myc has a positive role in upregulating Axl and itself under Arg-depleting stress, but a negative role in regulating Axl and c-Myc when ASS1 expression is elevated. Although the exact mechanisms underlying these differential regulation mechanisms are not clear at this time, however, this may not be surprising. c-Myc contains several highly conserved domains that are interactive with various binding partners (TRRAP, TIP60, TIP48, p400, Skp2 and so on), which can function in positive and negative regulation modes. 47, 48 The carboxy-terminal region of c-Myc comprises the basic helix-loop-helix leucine zipper domain, which can dimerize with other helix-loop-helix leucine zipper members that are essential for Myc's transcriptional regulation through E-box DNA binding. Dimerization of c-Myc and Max confers positive regulation, 49, 50 whereas with MIZI (also known as ABTB1) mediates repression of target genes. 51 In addition, c-Myc can regulate rates of transcriptional elongation. 52 Further investigations are needed to elucidate how c-Myc performs bi-directional regulation in controlling the overall Arg-auxotrophic response. In a broader aspect, because c-Myc is involved in regulating 15-20% of total genes in human genome, 53, 54 Arg-auxotrophic response is likely to have effects on global cancer metabolism. Of note is that mechanisms of Gas6/Axl in Arg-auxotrophic involvement differ from those found in other amino-acid depletions such as histidine, leucine 55, 56 or asparagine, 57 which involve the conserved GCN2/elf2α and mTOR signaling. 58, 59 Our present findings may have the following important therapeutic implications. First, in addition to previously demonstrated ASS1 induction, 5, 6 the present study demonstrated that enhanced Gas6/Axl expression in cancer cell lines including those derived from melanoma patients suggest that Gas6/Axl are likely important prognostic markers for the treatment outcomes, although more studies are needed. Gas6 secretion is an early event of ADI treatment and Gas6 concentration in human plasma is lower than 0.5 nM; 60, 61 therefore, development of highly sensitive Gas6 assay for liquid specimens will be very helpful. Second, Gas6/Axl may become viable targets in drug development for cancer chemotherapy. We demonstrated that inhibitors of Gas6 (warfarin) and Axl (bosutinib) can suppress the Argauxotrophic effects and enhance the cell-killing ability of ADI in Arg-auxotrophic cells. Warfain (trade name: Coumadin, Jantoven and Marevan) is a relatively safe Food and Drug Administrationapproved antithrombosis and antithromboembolism drug. Moreover, targeting Axl using small molecules 39, 62, 63 has been under clinical evaluations for cancer therapy. Third, these treatment developments are particularly compelling, because they can target malignant melanoma independently of BRAF mutations. Thus, our findings have important implications for improving the treatment efficacy of targeted therapy of Arg-auxotrophic tumors.
MATERIALS AND METHODS
The methods including reagents, cell culture and antibodies; plasmid DNA construction and shRNA transfection; phospho-RTK array analysis; activated RAS pull-down assay; IP and immunoblotting; western blotting analysis in Gas6 secretion; detection of intracellular ROS; establishment of primary cultures; aAnalysis of TCGA data; other procedures including cytotoxicity determination using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) or SRB (Life Technologies, Grand Island, NY, USA) and DNA fragmentation (apoptosis) assays are provided in the Supplementary Information. 5, 6 
